That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

Samuel C. Blackman net worth and biography

Samuel Blackman Biography and Net Worth

Insider of Day One Biopharmaceuticals

Sam Blackman, co-founder and Chief Medical Officer of Day One, is a physician-scientist trained in pediatric hematology/oncology and neuro-oncology, and has led the early clinical development of more than 10 novel cancer therapeutics. Prior to founding Day One, Dr. Blackman was Head of Clinical Development at Mavupharma, where he led the advancement of a novel immunotherapeutic towards Phase 1 clinical trials. Prior to Mavupharma he was Head of Clinical Development at Silverback Therapeutics. Prior to Silverback, Dr. Blackman held roles of increasing responsibility at Juno Therapeutics, Seattle Genetics, Merck, and GlaxoSmithKline. Dr. Blackman was responsible for the pediatric development of dabrafenib, resulting in the first industry-sponsored pediatric oncology “basket trial”. Through roles at CureSearch and ACCELERATE, Dr. Blackman is an active leader in the pediatric oncology drug development community.

Dr. Blackman is a graduate of the pediatric hematology/oncology fellowship program at the Dana-Farber Cancer Institute and Children’s Hospital Boston, and the pediatric residency program at Cincinnati Children’s Hospital Medical Center. He received his MD and PhD degrees from the University of Illinois at Chicago.

What is Samuel C. Blackman's net worth?: The estimated net worth of Samuel C. Blackman is at least $14.40 million as of November 11th, 2024. Dr. Blackman owns 1,057,535 shares of Day One Biopharmaceuticals stock worth more than $14,403,627 as of November 21st. This net worth approximation does not reflect any other investments that Dr. Blackman may own. Additionally, Dr. Blackman receives a salary of $651,000.00 as Insider at Day One Biopharmaceuticals. Learn More about Samuel C. Blackman's net worth.
How old is Samuel C. Blackman?: Dr. Blackman is currently 55 years old. There are 4 older executives and no younger executives at Day One Biopharmaceuticals. The oldest executive at Day One Biopharmaceuticals is Mr. Adam Dubow, General Counsel, who is 57 years old. Learn More on Samuel C. Blackman's age.
What is Samuel C. Blackman's salary?: As the Insider of Day One Biopharmaceuticals, Inc., Dr. Blackman earns $651,000.00 per year. There are 2 executives that earn more than Dr. Blackman. The highest earning executive at Day One Biopharmaceuticals is Dr. Jeremy Bender M.B.A., Ph.D., CEO, President & Director, who commands a salary of $900,000.00 per year. Learn More on Samuel C. Blackman's salary.
How do I contact Samuel C. Blackman?: The corporate mailing address for Dr. Blackman and other Day One Biopharmaceuticals executives is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. Day One Biopharmaceuticals can also be reached via phone at 650-484-0899 and via email at [email protected]. Learn More on Samuel C. Blackman's contact information.
Has Samuel C. Blackman been buying or selling shares of Day One Biopharmaceuticals?: Within the last three months, Samuel C. Blackman has sold $349,267.35 in Day One Biopharmaceuticals stock. Most recently, Samuel C. Blackman sold 10,000 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $16.10, for a transaction totalling $161,000.00. Following the completion of the sale, the insider now directly owns 1,057,535 shares of the company's stock, valued at $17,026,313.50. Learn More on Samuel C. Blackman's trading history.
Who are Day One Biopharmaceuticals' active insiders?: Day One Biopharmaceuticals' insider roster includes Samuel Blackman (Insider), and Papanek Grant (Director). Learn More on Day One Biopharmaceuticals' active insiders.
Are insiders buying or selling shares of Day One Biopharmaceuticals?: During the last twelve months, insiders at the sold shares 26 times. They sold a total of 321,808 shares worth more than $5,289,329.99. The most recent insider tranaction occured on November, 11th when insider Samuel C Blackman sold 10,000 shares worth more than $161,000.00. Insiders at Day One Biopharmaceuticals own 8.4% of the company. Learn More about insider trades at Day One Biopharmaceuticals.
Information on this page was last updated on 11/11/2024.

Samuel C. Blackman Insider Trading History at Day One Biopharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/11/2024	Sell	10,000	$16.10	$161,000.00	1,057,535
11/7/2024	Sell	11,245	$16.03	$180,257.35	1,085,790
10/31/2024	Sell	500	$16.02	$8,010.00	1,097,035
9/10/2024	Sell	30,000	$14.22	$426,600.00	1,097,535
8/16/2024	Sell	2,232	$14.00	$31,248.00	1,127,535
7/16/2024	Sell	20,000	$16.01	$320,200.00	1,121,081
5/16/2024	Sell	2,267	$16.08	$36,453.36	1,171,081
5/10/2024	Sell	10,000	$16.37	$163,700.00	1,164,662
4/18/2024	Sell	10,000	$16.02	$160,200.00	1,174,662
3/25/2024	Sell	10,000	$16.01	$160,100.00	1,184,662
2/27/2024	Sell	20,000	$16.11	$322,200.00	1,224,662
2/16/2024	Sell	2,258	$15.25	$34,434.50	1,244,662
11/16/2023	Sell	709	$11.69	$8,288.21	1,238,234
8/17/2023	Sell	668	$13.86	$9,258.48	1,236,319
6/5/2023	Sell	1,229	$16.00	$19,664.00	1,234,363
5/16/2023	Sell	692	$13.12	$9,079.04	1,235,592
3/10/2023	Sell	10,000	$18.05	$180,500.00	1,233,660
2/16/2023	Sell	674	$19.57	$13,190.18	1,243,660
2/10/2023	Sell	10,000	$20.07	$200,700.00	1,241,710
1/10/2023	Sell	10,000	$22.86	$228,600.00	1,250,148
12/1/2022	Sell	10,000	$21.45	$214,500.00	1,260,148
11/16/2022	Sell	377	$21.46	$8,090.42	1,270,148
8/16/2022	Sell	941	$24.31	$22,875.71	1,299,338
8/1/2022	Sell	10,000	$16.88	$168,800.00	1,296,718
7/1/2022	Sell	10,000	$18.72	$187,200.00	1,306,718
6/15/2022	Sell	50,000	$16.26	$813,000.00	1,316,718
1/3/2022	Sell	10,000	$17.10	$171,000.00
12/1/2021	Sell	10,000	$17.22	$172,200.00

Samuel C. Blackman Buying and Selling Activity at Day One Biopharmaceuticals

Day One Biopharmaceuticals Company Overview

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Today's Range

Now: $13.62

$13.32

$13.71

50 Day Range

MA: $14.37

$13.01

$16.39

2 Week Range

Now: $13.62

$11.30

$18.07

Volume

502,368 shs

Average Volume

958,997 shs

Market Capitalization

$1.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Breaking News: Tesla headed to $500…

From WealthPress | Ad

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

Samuel Blackman Biography and Net Worth

What is Samuel C. Blackman's net worth?

How old is Samuel C. Blackman?

What is Samuel C. Blackman's salary?

How do I contact Samuel C. Blackman?

Has Samuel C. Blackman been buying or selling shares of Day One Biopharmaceuticals?

Who are Day One Biopharmaceuticals' active insiders?

Are insiders buying or selling shares of Day One Biopharmaceuticals?

Samuel C. Blackman Insider Trading History at Day One Biopharmaceuticals

Samuel C. Blackman Buying and Selling Activity at Day One Biopharmaceuticals

Day One Biopharmaceuticals Company Overview

Today's Range

50 Day Range

2 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta